Prevention of pulmonary hypertension by angiotensin-converting enzyme 2 gene transfer

Hypertension

Volumn 54, Issue 2, 2009, Pages 365-371

  Yamazato, Yoriko ^a   Ferreira, Anderson J ^a,c   Hong, Kwon Ho ^a   Sriramula, Srinivas ^d   Francis, Joseph ^d   Yamazato, Masanobu ^a   Yuan, Lihui ^a   Bradford, Chastity N ^a   Shenoy, Vinayak ^b   Oh, Suk P ^a   Katovich, Michael J ^b   Raizada, Mohan K ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA HEALTH   (United States)

^c FEDERAL UNIVERSITY OF MINAS GERAIS   (Brazil)

^d LOUISIANA STATE UNIVERSITY   (United States)

Author keywords

Cardiovascular diseases; Gene therapy; Hypertension; Lung; Pulmonary; Remodeling

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN CONVERTING ENZYME 2; DIPEPTIDYL CARBOXYPEPTIDASE; LENTIVIRUS VECTOR; MESSENGER RNA; MONOCROTALINE; RENIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; GENE OVEREXPRESSION; GENE TRANSFER; HEART RIGHT VENTRICLE PRESSURE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY HYPERTENSION; ANALYSIS OF VARIANCE; ANIMAL; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; COMPARATIVE STUDY; DISEASE MODEL; DRUG EFFECT; GENETICS; PROBABILITY; RANDOMIZATION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SENSITIVITY AND SPECIFICITY; SUBCUTANEOUS DRUG ADMINISTRATION;

ANALYSIS OF VARIANCE; ANIMALS; DISEASE MODELS, ANIMAL; GENE TRANSFER TECHNIQUES; HYPERTENSION, PULMONARY; INFUSIONS, SUBCUTANEOUS; MALE; MICE; MICE, INBRED C57BL; MONOCROTALINE; PEPTIDYL-DIPEPTIDASE A; PROBABILITY; RANDOM ALLOCATION; RENIN-ANGIOTENSIN SYSTEM; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY;

EID: 68549122789     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.108.125468     Document Type: Article

References (51)

1. Coggins MP, Bloch KD. Nitric oxide in the pulmonary vasculature. Arterioscler Thromb Vasc Biol. 2007;27:1877-1885.
2. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: cellular and molecular mechanisms. Circ Res. 2006;99:675-691.
3. Studdy PR, Lapworth R, Bird R. Angiotensin-converting enzyme and its clinical significance - a review. J Clin Pathol. 1983;36:938-947.
4. Marshall RP. The pulmonary renin-angiotensin system. Curr Pharm Des. 2003;9:715-722.
5. Dezsö B, Nielsen AH, Poulsen K. Identification of renin in resident alveolar macrophages and monocytes: HPLC and immunohistochemical study. J Cell Sci. 1988;91:155-159.
6. Ohkubo H, Nakayama K, Tanaka T, Nakanishi S. Tissue distribution of rat angiotensinogen mRNA and structural analysis of its heterogeneity. J Biol Chem. 1986;261:319-323.
7. Chassagne C, Eddahibi S, Adamy C, Rideau D, Marotte F, Dubois-Randé JL, Adnot S, Samuel JL, Teiger E. Modulation of angiotensin II receptor expression during development and regression of hypoxic pulmonary hypertension. Am J Respir Cell Mol Biol. 2000;22:323-332.
8. Bullock GR, Steyaert I, Bilbe G, Carey RM, Kips J, De Paepe B, Pauwels R, Praet M, Siragy HM, de Gasparo M. Distribution of type-1 and type-2 angiotensin receptors in the normal human lung and in lungs from patients with chronic obstructive pulmonary disease. Histochem Cell Biol. 2001;115:117-124.
9. Lefebvre F, Préfontaine A, Calderone A, Caron A, Jasmin JF, Villeneuve L, Dupuis J. Modification of the pulmonary renin-angiotensin system and lung structural remodelling in congestive heart failure. Clin Sci (Lond). 2006;111:217-224.
10. DeMarco VG, Habibi J, Whaley-Connell AT, Schneider RI, Heller RL, Bosanquet JP, Hayden MR, Delcour K, Cooper SA, Andresen BT, Sowers JR, Dellsperger KC. Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol. 2008;294:H2659-H2668.
11. Morrell NW, Morris KG, Stenmark KR. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol. 1995;269:H1186-H1194.
12. Orte C, Polak JM, Haworth SG, Yacoub MH, Morrell NW. Expression of pulmonary vascular angiotensin-converting enzyme in primary and secondary plexiform pulmonary hypertension. J Pathol. 2000;192:379-384.
13. Cassis L, Shenoy U, Lipke D, Baughn J, Fettinger M, Gillespie M. Lung angiotensin receptor binding characteristics during the development of monocrotaline-induced pulmonary hypertension. Biochem Pharmacol. 1997;54:27-31.
14. Molteni A, Ward WF, Ts'ao CH, Solliday NH. Monocrotaline-induced cardiopulmonary damage in rats: amelioration by the angiotensinconverting enzyme inhibitor CL242817. Proc Soc Exp Biol Med. 1986;182:483-493.
15. Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: a target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther. 2001;92:1-20.
16. Mascitelli L, Pezzetta F. Inhibition of the renin-angiotensin system in patients with COPD and pulmonary hypertension. Chest. 2007;131:938.
17. Reid JL. ACE inhibitors: future perspectives. J Cardiovasc Pharmacol. 1993;22:541-543.
18. Seist G, Jeannesson E, Visvikis-Seist S. Enzymes and pharmacogenomics of cardiovascular drugs. Clin Chim Acta. 2007;381:26-31.
19. Shah AD, Arora RR. Do all patients with coronary artery disease benefit from angiotensin converting enzyme inhibitors? J Cardiovasc Pharmacol Ther. 2005;10:281-283.
20. Dandona P, Dhindsa S, Ghanim H, Chaudhuri A. Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade. J Hum Hypertens. 2007;21:20-27.
21. Hunyady L, Catt KJ. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Mol Endocrinol. 2006;20:953-970.
22. Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. J Biol Chem. 2002;277:14838-14843.
23. Der Sarkissian S, Huentelman MJ, Stewart J, Katovich MJ, Raizada MK. ACE2: a novel therapeutic target for cardiovascular diseases. Prog Biophys Mol Biol. 2006;91:163-198.
24. Raizada MK, Ferreira AJ. ACE2: a new target for cardiovascular disease therapeutics. J Cardiovasc Pharmacol. 2007;50:112-119.
25. Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM. A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med. 2005;11:875-879.
26. Imai Y, Kuba K, Penninger JM. Angiotensin-converting enzyme 2 in acute respiratory distress syndrome. Cell Mol Life Sci. 2007;64: 2006-2012.
27. Yamamoto K, Ohishi M, Katsuya T, Ito N, Ikushima M, Kaibe M, Tatara Y, Shiota A, Sugano S, Takeda S, Rakugi H, Ogihara T. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertens. 2008;47:718-726.
28. Li X, Molina-Molina M, Abdul-Hafez A, Uhal V, Xaubet A, Uhal BD. Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2008;295:L178-L185.
29. Zisman LS, Keller RS, Weaver B, Lin Q, Speth R, Bristow MR, Canver CC. Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of angiotensin-converting enzyme homologue ACE2. Circ. 2003;108:1707-1712.
30. Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM. Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 2005;436:112-116.
31. Grobe JL, Mecca AP, Mao H, Katovich MJ. Chronic angiotensin-(1-7) prevents cardiac fibrosis in the DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol. 2006;290:H2417-H2423.
32. Hessel MHM, Steendijk P, den Adel B, Schutte CI, van der Laarse A. Characterization of right ventricular function after monocrotaline-induced pulmonary hypertension in the intact rat. Am J Physiol Heart Circ Physiol. 2006;291:H2424-H2430.
33. Tsutsumi Y, Matsubara H, Ohkubo N, Mori Y, Nozawa Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Moriguchi Y, Shibasaki Y, Kamihata H, Inada M, Iwasaka T. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ Res. 1998;83:1035-1046.
34. Zhu YZ, Chimon GN, Zhu YC, Lu Q, Li B, Hu HZ, Yap EH, Lee HS, Wong PT. Expression of angiotensin II AT2 receptor in the acute phase of stroke in rats. Neuroreport. 2000;11:1191-1204.
35. Ferreira AJ, Shenoy V, Yamazato Y, Sriramula S, Francis J, Yuan L, Castellano RK, Ostrov DA, Oh SP, Katovich MJ, Raizada MK. Evidence for angiotensin converting enzyme 2 as a therapeutic target for the prevention of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179:1048-1054.
36. Shenoy V, Ferreira AJ, Qi Y, Dooies KA, Raizada MK, Katovich MJ. Lenti-viral mediated overexpression of ACE2 or angiotensin-(1-7) prevents bleomycin-induced pulmonary fibrosis. FASEB J. 2009;23: 770.7.
37. Booz GW, Baker KM. Role of type 1 and type 2 angiotensin receptors in angiotensin II-induced cardiomyocyte hypertrophy. Hypertension. 1996;28:635-640.
38. Feng Y, Yue X, Xia H, Bindom SM, Hickman PJ, Filipeanu CM, Wu G, Lazartigues E. Angiotensin-converting enzyme 2 overexpression in the subfornical organ prevents the angiotensin II-mediated pressor and drinking responses and is associated with angiotensin II type 1 receptor downregulation. Circ Res. 2008;102:729-736.
39. Schober A, Zernecke A. Chemokines in vascular remodeling. Thromb Haemost. 2007;97:730-737.
40. Ferrario CM, Strawn WB. Role of the renin-angiotensin system and proinflammatory mediators in cardiovascular disease. Am J Cardiol. 2006;58:81-88.
41. Huentelman MJ, Grobe JL, Vazquez J, Steward JM, Mecca AP, Katovich MJ, Ferrario CM, Raizada MK. Protection from angiotension II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Exp Physiol. 2005;90:783-790.
42. Packer M. Vasodilator therapy for primary pulmonary hypertension. Limitations and hazards. Ann Intern Med. 1985;103:258-270.
43. Rubin LJ, Badesch DB. Evaluation and management of the patient with pulmonary arterial hypertension. Ann Intern Med. 2005;143:282-292.
44. Coleman JE, Huentelman MJ, Katovich MJ, Semple-Rowland SL, Raizada MK. Efficient large-scale production and concentration of HIV-based lentiviral vectors for use in vivo. Physiol Genomics. 2003;12:221-228.
45. Díez-Freire C, Vázquez J, Correa de Adjounian MF, Ferrari MF, Yuan L, Silver X, Torres R, Raizada MK. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiol Genomics. 2006;27:12-19.
46. Jones R, Jacobson M, Steudel W. α-Smooth-muscle actin and microvascular precursor smooth-muscle cells in pulmonary hypertension. Am J Respir Cell Mol Biol.1999; 20: 582-594.
47. Rabinovitch M, Gamble WJ, Miettinen OS, Reid L. Age and sex influence on pulmonary hypertension of chronic hypoxia and on recovery. Am J Physiol. 1981;240:H62-H72
48. Beppu H, Ichinose F, Kawai N, Jones RC, Yu PB, Zapol WM, Miyazono K, Li E, Bloch KD. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol. 2004;287:L1241-L1247.
49. Eddahibi S, Hanoun N, Lanfumey L, Lesch KP, Raffestin B, Hamon M, Adnot S. Attenuated hypoxic pulmonary hypertension in mice lacking the 5-hydroxytryptamine transporter gene. J Clin Invest. 2000;105:1555-1562.
50. Botelho LMO, Block CH, Khosla MC, Santos RAS. Plasma angiotensin-(1-7) immunoreactivity is increased by salt load, water deprivation, and hemorrhage. Peptides. 1994;15:723-729.
51. 1-R and cytokines in the hypothalamic paraventricular nucleus. Eur J Heart Fail. 2008;10:625-634.